BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26725885)

  • 1. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
    Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL
    J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
    Kim WJ; Dho YS; Ock CY; Kim JW; Choi SH; Lee ST; Kim IH; Kim TM; Park CK
    J Neurooncol; 2019 Jun; 143(2):321-328. PubMed ID: 30982199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
    O'Leary B; Mandeville HC; Fersht N; Solda F; Mycroft J; Zacharoulis S; Vaidya S; Saran F
    J Neurooncol; 2016 Apr; 127(2):295-302. PubMed ID: 26842817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era.
    Byun HK; Kim N; Yoon HI; Kang SG; Kim SH; Cho J; Baek JG; Chang JH; Suh CO
    Radiat Oncol; 2019 Mar; 14(1):51. PubMed ID: 30917849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
    Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
    Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
    Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
    Huang J; DeWees TA; Badiyan SN; Speirs CK; Mullen DF; Fergus S; Tran DD; Linette G; Campian JL; Chicoine MR; Kim AH; Dunn G; Simpson JR; Robinson CG
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1000-1007. PubMed ID: 26025775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
    Fiorentino A; Balducci M; De Bonis P; Chiesa S; De Filippo L; Mangiola A; De Rose F; Autorino R; Rinaldi C; Fersino S; Diletto B; Matteucci P; Ciurlia E; Fusco V; Anile C; Valentini V
    Am J Clin Oncol; 2015 Feb; 38(1):23-7. PubMed ID: 23388566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
    Nachbichler SB; Schupp G; Ballhausen H; Niyazi M; Belka C
    Strahlenther Onkol; 2017 Nov; 193(11):890-896. PubMed ID: 28197654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
    Rhee DJ; Kong DS; Kim WS; Park KB; Lee JI; Suh YL; Song SY; Kim ST; Lim DH; Park K; Kim JH; Nam DH
    Clin Neurol Neurosurg; 2009 Nov; 111(9):748-51. PubMed ID: 19716649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
    Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
    Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide.
    Campian JL; Piotrowski AF; Ye X; Hakim FT; Rose J; Yan XY; Lu Y; Gress R; Grossman SA
    J Neurooncol; 2017 Nov; 135(2):343-351. PubMed ID: 28756593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.